Arkolith/Insider Trading/SABS/Form 4

Reich Samuel J

CEO & EXECUTIVE CHAIRMAN, DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Feb 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 21, 2024Grant(A)434K—$0434K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-019430) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML